Trial Details
RECRUITINGBasic Information
| Clinical ID | c226 |
|---|---|
| Identifier | NCT06937086 |
| Trial Title | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis|Obesity or Overweight |
| Interventions | DRUG: Mirikizumab|DRUG: Mirikizumab|DRUG: Tirzepatide|DRUG: Placebo |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Dothan |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2025-06-26 |
|---|---|
| Primary Completion Date | 2028-04 |
| Completion Date | 2028-04 |